- Stocks
- Healthcare
- NASDAQ: EDIT

Price (delayed)

$41.54

Market cap

$2.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$2.49B

EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter

Editas Medicine's quick ratio has surged by 62% YoY and by 40% QoQ

EDIT's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter

Editas Medicine's net income has decreased by 16% QoQ but it has increased by 5% YoY

The debt has grown by 11% from the previous quarter and by 6% YoY

What are the main financial stats of EDIT

Market
Valuations
Earnings

Shares outstanding

67.83M

Market cap

$2.82B

Enterprise value

$2.49B

Price to earnings (P/E)

N/A

Price to book (P/B)

4.39

Price to sales (P/S)

29.96

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

27.23

Revenue

$91.51M

EBIT

-$136.16M

EBITDA

-$131.84M

Free cash flow

-$180.32M

Per share
Balance sheet
Liquidity

EPS

-$2.21

Free cash flow per share

-$2.73

Book value per share

$9.47

Revenue per share

$1.39

TBVPS

$11.82

Total assets

$780.29M

Total liabilities

$142.3M

Debt

$28.89M

Equity

$638M

Working capital

$568.31M

Debt to equity

0.05

Current ratio

9.88

Quick ratio

9.78

Net debt/EBITDA

2.47

Margins
Efficiency
Dividend

EBITDA margin

-144.1%

Gross margin

100%

Net margin

-147.5%

Operating margin

-158.6%

Return on assets

-20.7%

Return on equity

-28.4%

Return on invested capital

-45%

Return on capital employed

-19%

Return on sales

-148.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Editas Medicine stock price performed over time

Intraday

-0.76%

1 week

4.24%

1 month

-24.34%

1 year

41.49%

YTD

-40.75%

QTD

-26.66%

How have Editas Medicine's revenue and profit performed over time

Revenue

$91.51M

Gross profit

$91.51M

Operating income

-$145.11M

Net income

-$134.98M

Gross margin

100%

Net margin

-147.5%

The net margin has soared by 75% YoY but it has contracted by 15% from the previous quarter

EDIT's operating margin has surged by 75% year-on-year but it is down by 7% since the previous quarter

Editas Medicine's net income has decreased by 16% QoQ but it has increased by 5% YoY

EDIT's operating income is down by 8% since the previous quarter but it is up by 7% year-on-year

What is Editas Medicine's growth rate over time

What is Editas Medicine stock price valuation

P/E

N/A

P/B

4.39

P/S

29.96

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

27.23

EDIT's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter

EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter

EDIT's P/B is 24% below its last 4 quarters average of 5.8 and 19% below its 5-year quarterly average of 5.4

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 76% year-on-year but it is down by 14% since the previous quarter

The ROE has soared by 55% YoY and by 8% from the previous quarter

EDIT's return on invested capital is up by 44% year-on-year and by 3.8% since the previous quarter

Editas Medicine's ROA has increased by 38% YoY but it has decreased by 2.5% from the previous quarter

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

How did Editas Medicine financials performed over time

EDIT's total assets has soared by 67% YoY and by 36% QoQ

Editas Medicine's quick ratio has surged by 62% YoY and by 40% QoQ

The debt is 95% less than the equity

EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter

The company's debt to equity has shrunk by 58% YoY and by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.